{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T21:14:44Z","timestamp":1771103684625,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro\/Brazil (FAPERJ)"},{"name":"Donald P. Goldstein MD Trophoblastic Tumor Registry Endowment"},{"name":"Dyett Family Trophoblastic Disease Research and Registry Endowment"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics &amp; Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ejogrb.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T13:17:18Z","timestamp":1518700638000},"page":"50-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Does a human chorionic gonadotropin level of over 20,000\u202fIU\/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?"],"prefix":"10.1016","volume":"223","author":[{"given":"Antonio","family":"Braga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andressa","family":"Biscaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessye Melgarejo","family":"do Amaral Giordani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maur\u00edcio","family":"Viggiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross S.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Seckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2018.02.001_bib0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ajog.2010.06.073","article-title":"Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole","volume":"203","author":"Lurain","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0010","doi-asserted-by":"crossref","first-page":"vi39","DOI":"10.1093\/annonc\/mdt345","article-title":"Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Seckl","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0015","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.AOG.0000174583.51617.25","article-title":"Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy","volume":"106","author":"Wolfberg","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0020","first-page":"241","article-title":"Epidemiological report on the treatment of patients with gestational trophoblastic disease in 10 Brazilian referral centers","volume":"59","author":"Braga","year":"2014","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajog.2010.06.072","article-title":"Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia","volume":"204","author":"Lurain","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.hoc.2011.10.007","article-title":"Current management of gestational trophoblastic neoplasia","volume":"26","author":"Goldstein","year":"2012","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1590\/SO100-720320140005198","article-title":"Diagnosis, classification and treatment of gestational trophoblastic neoplasia","volume":"37","author":"Biscaro","year":"2015","journal-title":"Rev Bras Ginecol Obstet"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0020-7292(02)00063-2","article-title":"FIGO staging for gestational trophoblasticneoplasia 2000","volume":"77","author":"FIGO Oncology Committee","year":"2002","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0140-6736(11)61265-8","article-title":"Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study","volume":"379","author":"Agarwal","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0050","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000073843","article-title":"Criteria for initiating chemotherapy in patients after evacuation of hydatidiform mole","volume":"24","author":"Matsui","year":"2003","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0055","series-title":"Gestational trophoblastic disease. Chapter 10","first-page":"277","article-title":"Presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours (GTT) in the United Kingdom","author":"Seckl","year":"2009"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0060","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1471-0528.1973.tb15962.x","article-title":"Follow-up after hydatidiform mole: studies using radioimmunoassay for urinary human chorionic gonadotrophin (HCG)","volume":"80","author":"Bagshawe","year":"1973","journal-title":"J Obstet Gynaecol Br Commonw"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0065","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO;2-E","article-title":"Risk and prognostic factors in trophoblastic neoplasia","volume":"38","author":"Bagshawe","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0070","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(10)60280-2","article-title":"Gestational trophoblastic disease","volume":"376","author":"Seckl","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0075","first-page":"213","article-title":"Histopathological and immunohistochemical features of early hydatidiform mole in relation to subsequent development of persistent gestational trophoblastic disease","volume":"59","author":"Petts","year":"2014","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0080","first-page":"CD007289","article-title":"Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia","volume":"10","author":"Fu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0085","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0090","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0002-9378(78)90829-3","article-title":"The syndromes of hydatidiform mole: I. Cytogenetic and morphological correlations","volume":"131","author":"Szulman","year":"1978","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0095","first-page":"1723","article-title":"Updated diagnostic criteria for partial and complete hydatidiform moles in early pregnancy","volume":"23","author":"Sebire","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0100","first-page":"269","article-title":"Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease","volume":"78","author":"Chilosi","year":"1998","journal-title":"Lab Invest"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0105","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1093\/clinchem\/43.12.2233","article-title":"Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites","volume":"43","author":"Cole","year":"1997","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/01443615.2013.771159","article-title":"The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome","volume":"33","author":"Savage","year":"2013","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.fertnstert.2015.06.001","article-title":"Postmolar gestational trophoblastic neoplasia: beyond the traditional risk factors","volume":"104","author":"Mirzamoradi","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0120","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ygyno.2011.10.035","article-title":"Prediction of persistent gestational trophoblastic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole","volume":"124","author":"Kang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0125","first-page":"732","article-title":"Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation","volume":"101","author":"Feltmate","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0130","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(86)90179-0","article-title":"Hydatidiform mole in England and Wales 1973\u201383","volume":"2","author":"Bagshawe","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2018.02.001_bib0135","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(04)16898-0","article-title":"Routine terminations of pregnancy-should we screen for gestational trophoblastic neoplasia?","volume":"364","author":"Seckl","year":"2004","journal-title":"Lancet"}],"container-title":["European Journal of Obstetrics &amp; Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211518300496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211518300496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:41:06Z","timestamp":1759556466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211518300496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":27,"alternative-id":["S0301211518300496"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2018.02.001","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does a human chorionic gonadotropin level of over 20,000\u202fIU\/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}